Shares of Northwest Biotherapeutics, Inc. (NWBO) plunged more than 21% Friday after some blogs and social media comments have noted that the EudraCT trials database in Europe states that there is a "Temporary Halt" in Germany of the company's current phase 3 clinical trial that is evaluating DCVax-L as a treatment for Glioblastoma multiform, a lethal brain cancer.
Minutes before the market closed, NWBO announced that its Phase III trial of DCVax-L is ongoing and the patients enrolled in the trial are continuing to be treated per the protocol.
According to NWBO, the only change in status of the trial is that new screening of patient candidates for the trial has been temporarily suspended while the company submits certain information from the trial for regulatory review. Such screening involves the initial evaluation of patient candidates to determine whether they meet eligibility criteria for the trial (e.g., whether they are within the eligible age range, do not have certain viral diseases, etc.)
NWBO said that it has sought to have the EudraCT listing corrected, but the database includes only certain pre-specified categories and there is no category that corresponds to a temporary suspension of new screening only, while a trial is ongoing.
NWBO also stated that it is in the process of preparing the trial information for regulatory review and anticipates submission within the next couple of weeks.
NWBO is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe.
More about Northwest Biotherapeutics, Inc. (NWBO) at www.nwbio.com
Brokerage firm UBS raised its price target on shares of Williams-Sonoma Inc. (WSM) to $87.00 from $84.00. The firm maintained its Neutral rating.
WSM will release its second quarter fiscal 2015 results on Wednesday, August 26, 2015, after the market close.
WSM is a specialty retailer of high-quality products for the home.
More about Williams-Sonoma Inc. (WSM) at www.williams-sonomainc.com
Crown Equity Holdings Inc. (CRWE) provides marketing solutions that boost customer awareness and merchant visibility on the Internet.
The company is currently developing its CRWE WORLD ( www.crweworld.com ), a community targeted platform which goal is to be a one-stop shop for the various needs of online consumers in a range of marketing specialties like Real Estate, Coupons & Deals, Business Directory and more
CRWE WORLD’s business model is based on selling advertising to businesses targeting their marketing message locally, nationally, internationally and also to target potential clients for an specific location, such as within a certain zip code.
The company’s CRWE Real Estate ( www.CRWERealEstate.com ) is expected to be integrated in all the CRWE WORLD Network. It will allow people to submit their listings for exposure to visitors searching for homes.
More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer
Northwest Biotherapeutics Inc. (NWBO) Stock Research Links